ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION) A Randomized Clinical Trial
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION) A Randomized Clinical Trial |
Type de publication | Journal Article |
Year of Publication | 2021 |
Auteurs | Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MClaude, Wilson K, Kim W-K, Meneveau N, Hambrecht R, Byrne J, Carrie D, Fraser D, Roberts DH, Doshi SN, Zaman A, Banning AP, Eltchaninoff H, Le Breton H, Smith D, Cox I, Frank D, Gershlick A, de Belder M, Thomas M, Hildick-Smith D, Prendergast B, Redwood S, Investigators ACTIVATIONTrial |
Journal | JACC-CARDIOVASCULAR INTERVENTIONS |
Volume | 14 |
Pagination | 1965-1974 |
Date Published | SEP 27 |
Type of Article | Article |
ISSN | 1936-8798 |
Mots-clés |  , aortic stenosis, percutaneous coronary intervention, randomized control trial, Transcatheter aortic valve replacement |
Résumé | OBJECTIVES This study sought to determine if percutaneous coronary intervention (PCI) prior to transcatheter aortic valve replacement (TAVR) in patients with significant coronary artery disease would produce noninferior clinical results when compared with no PCI (control arm). BACKGROUND PCI in patients undergoing TAVR is not without risk, and there are no randomized data to inform clinical practice. METHODS Patients with severe symptomatic aortic stenosis and significant coronary artery disease with Canadian Cardiovascular Society class \#2 angina were randomly assigned to receive PCI or no PCI prior to TAVR. The primary endpoint was a composite of all-cause death or rehospitalization at 1 year. Noninferiority testing (prespecified margin of 7.5%) was performed in the intention-to-treat population. RESULTS At 17 centers, 235 patients underwent randomization. At 1 year, the primary composite endpoint occurred in 48 (41.5%) of the PCI arm and 47 (44.0%) of the no-PCI arm. The requirement for noninferiority was not met (difference:-2.5%; 1-sided upper 95% confidence limit: 8.5%; 1-sided noninferiority test P = 0.067). On analysis of the as-treated population, the difference was-3.7% (1-sided upper 95% confidence limit: 7.5%; P = 0.050). Mortality was 16 (13.4%) in the PCI arm and 14 (12.1%) in the no-PCI arm. At 1 year, there was no evidence of a difference in the rates of stroke, myocardial infarction, or acute kidney injury, with higher rates of any bleed in the PCI arm (P = 0.021). CONCLUSIONS Observed rates of death and rehospitalization at 1 year were similar between PCI and no PCI prior to TAVR; however, the noninferiority margin was not met, and PCI resulted in a higher incidence of bleeding. (Assessing the Effects of Stenting in Significant Coronary Artery Disease Prior to Transcatheter Aortic Valve Implantation; ISRCTN75836930) (J Am Coll Cardiol Intv 2021;14:1965-1974) (c) 2021 by the American College of Cardiology Foundation. |
DOI | 10.1016/j.jcin.2021.06.041 |